Alligator Bioscience AB (ATORX) - Net Assets
Based on the latest financial reports, Alligator Bioscience AB (ATORX) has net assets worth Skr6.86 Million SEK (≈ $738.14K USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr110.60 Million ≈ $11.90 Million USD) and total liabilities (Skr103.74 Million ≈ $11.16 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check ATORX asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr6.86 Million |
| % of Total Assets | 6.2% |
| Annual Growth Rate | 3.83% |
| 5-Year Change | -97.57% |
| 10-Year Change | -98.99% |
| Growth Volatility | 558.53 |
Alligator Bioscience AB - Net Assets Trend (2005–2025)
This chart illustrates how Alligator Bioscience AB's net assets have evolved over time, based on quarterly financial data. Also explore ATORX asset base for the complete picture of this company's asset base.
Annual Net Assets for Alligator Bioscience AB (2005–2025)
The table below shows the annual net assets of Alligator Bioscience AB from 2005 to 2025. For live valuation and market cap data, see Alligator Bioscience AB market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | Skr6.86 Million ≈ $738.14K |
+105.25% |
| 2024-12-31 | Skr-130.59 Million ≈ $-14.05 Million |
-1201.54% |
| 2023-12-31 | Skr11.86 Million ≈ $1.28 Million |
-86.69% |
| 2022-12-31 | Skr89.05 Million ≈ $9.58 Million |
-68.45% |
| 2021-12-31 | Skr282.27 Million ≈ $30.38 Million |
+144.94% |
| 2020-12-31 | Skr115.24 Million ≈ $12.40 Million |
-55.42% |
| 2019-12-31 | Skr258.50 Million ≈ $27.82 Million |
-44.80% |
| 2018-12-31 | Skr468.31 Million ≈ $50.40 Million |
-24.22% |
| 2017-12-31 | Skr617.96 Million ≈ $66.50 Million |
-8.61% |
| 2016-12-31 | Skr676.18 Million ≈ $72.77 Million |
+70.34% |
| 2015-12-31 | Skr396.97 Million ≈ $42.72 Million |
+479.36% |
| 2014-12-31 | Skr68.52 Million ≈ $7.37 Million |
+218.57% |
| 2011-12-31 | Skr21.51 Million ≈ $2.31 Million |
+1798.32% |
| 2010-12-31 | Skr1.13 Million ≈ $121.93K |
-90.99% |
| 2008-12-31 | Skr12.57 Million ≈ $1.35 Million |
-69.66% |
| 2007-12-31 | Skr41.44 Million ≈ $4.46 Million |
+279.97% |
| 2006-12-31 | Skr10.91 Million ≈ $1.17 Million |
+237.44% |
| 2005-12-31 | Skr3.23 Million ≈ $347.81K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Alligator Bioscience AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 409782.1% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr8.76 Million | 127.76% |
| Other Components | Skr1.30 Billion | 18966.10% |
| Total Equity | Skr6.86 Million | 100.00% |
Alligator Bioscience AB Competitors by Market Cap
The table below lists competitors of Alligator Bioscience AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Senior PLC
LSE:SNR
|
$14.34 Million |
|
Cloudastructure, Inc. Class A Common Stock
NASDAQ:CSAI
|
$14.34 Million |
|
Toppoint Holdings Inc.
NYSE MKT:TOPP
|
$14.35 Million |
|
Anugerah Kagum Karya Utama Tbk PT
JK:AKKU
|
$14.36 Million |
|
Tarmat Limited
NSE:TARMAT
|
$14.31 Million |
|
Barramundi Group Ltd
OL:BARRA
|
$14.30 Million |
|
Goodfood Market Corp
TO:FOOD
|
$14.30 Million |
|
Clal Biotechnology Industries Ltd
TA:CBI
|
$14.30 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Alligator Bioscience AB's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -130,588,000 to 6,859,000, a change of 137,447,000.
- Net loss of 51,350,000 reduced equity.
- Share repurchases of 307,434,000 reduced equity.
- New share issuances of 307,434,000 increased equity.
- Other factors increased equity by 188,797,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-51.35 Million | -748.65% |
| Share Repurchases | Skr307.43 Million | -4482.2% |
| Share Issuances | Skr307.43 Million | +4482.2% |
| Other Changes | Skr188.80 Million | +2752.54% |
| Total Change | Skr- | % |
Book Value vs Market Value Analysis
This analysis compares Alligator Bioscience AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.85x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.01x to 0.85x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-12-31 | Skr17.71 | Skr0.21 | x |
| 2015-12-31 | Skr88.61 | Skr0.21 | x |
| 2016-12-31 | Skr140.60 | Skr0.21 | x |
| 2017-12-31 | Skr108.36 | Skr0.21 | x |
| 2018-12-31 | Skr82.00 | Skr0.21 | x |
| 2019-12-31 | Skr45.26 | Skr0.21 | x |
| 2020-12-31 | Skr20.18 | Skr0.21 | x |
| 2021-12-31 | Skr42.63 | Skr0.21 | x |
| 2022-12-31 | Skr13.46 | Skr0.21 | x |
| 2023-12-31 | Skr2.23 | Skr0.21 | x |
| 2024-12-31 | Skr-15.04 | Skr0.21 | x |
| 2025-12-31 | Skr0.25 | Skr0.21 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Alligator Bioscience AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -748.65%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -9990.27%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 16.13x
- Recent ROE (-748.65%) is below the historical average (-277.48%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | -178.87% | -3107.51% | 0.04x | 1.42x | Skr-40.62 Million |
| 2014 | -112.06% | -6222.20% | 0.01x | 1.43x | Skr-83.63 Million |
| 2015 | 52.24% | 71.56% | 0.70x | 1.05x | Skr167.68 Million |
| 2016 | -7.15% | -83.03% | 0.08x | 1.04x | Skr-115.97 Million |
| 2017 | -10.32% | -112.10% | 0.09x | 1.04x | Skr-125.55 Million |
| 2018 | -32.04% | -556.56% | 0.05x | 1.09x | Skr-196.87 Million |
| 2019 | -81.44% | -4830.91% | 0.01x | 1.20x | Skr-236.38 Million |
| 2020 | -124.61% | -3299.84% | 0.03x | 1.32x | Skr-155.13 Million |
| 2021 | -50.21% | -1095.07% | 0.04x | 1.18x | Skr-169.96 Million |
| 2022 | -217.18% | -541.79% | 0.21x | 1.90x | Skr-202.30 Million |
| 2023 | -2096.89% | -427.81% | 0.49x | 9.99x | Skr-249.77 Million |
| 2024 | 0.00% | -404.89% | 0.55x | 0.00x | Skr-220.83 Million |
| 2025 | -748.65% | -9990.27% | 0.00x | 16.13x | Skr-52.04 Million |
Industry Comparison
This section compares Alligator Bioscience AB's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $175,780,327
- Average return on equity (ROE) among peers: -78.50%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Alligator Bioscience AB (ATORX) | Skr6.86 Million | -178.87% | 15.13x | $14.33 Million |
| 2cureX AB (2CUREX) | $74.34 Million | -25.47% | 0.06x | $4.90 Million |
| Ascelia Pharma AB (publ) (ACE) | $74.33 Million | -147.03% | 0.17x | $40.96 Million |
| AcouSort AB (ACOU) | $15.58 Million | -57.51% | 0.12x | $8.97 Million |
| Active Biotech AB (ACTI) | $188.64 Million | -118.73% | 1.64x | $17.19 Million |
| Alzinova AB (ALZ) | $20.63 Million | -16.51% | 0.08x | $4.97 Million |
| AlzeCure Pharma (ALZCUR) | $182.01 Million | -28.02% | 0.03x | $18.18 Million |
| Annexin Pharmaceuticals AB (ANNX) | $18.81 Million | -234.16% | 0.42x | $11.24 Million |
| BioInvent International AB (BINV) | $219.00 Million | -63.86% | 0.22x | $155.44 Million |
| BioArctic AB (publ) (BIOA-B) | $788.68 Million | -15.19% | 0.14x | $2.59 Billion |
About Alligator Bioscience AB
Alligator Bioscience AB (publ), a research-based biotechnology company, develops antibody-based pharmaceuticals for cancer treatment in Finland and Sweden. The company develops Mitazalimab, a stimulatory antibody that targets CD40, which is in phase 2 clinical trial for the treatment of solid metastatic tumors, including pancreatic cancer; and ATOR-4066, tumor-directed bispecific antibody, develo… Read more